{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:13:42Z","timestamp":1750227222212,"version":"3.37.3"},"reference-count":27,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015693","name":"Purdue Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2023,4,3]]},"DOI":"10.1080\/03007995.2023.2178080","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T08:29:15Z","timestamp":1676017755000},"page":"579-587","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the effectiveness of reformulated extended-release oxycodone with abuse-deterrent properties on reducing non-oral abuse among individuals assessed for substance abuse treatment with the Addiction Severity Index-Multimedia Version (ASI-MV)"],"prefix":"10.1080","volume":"39","author":[{"given":"Rachelle D.","family":"Rodriguez","sequence":"first","affiliation":[{"name":"Janssen Pharmaceuticals, LLC, Raritan, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taryn","family":"Dailey Govoni","sequence":"additional","affiliation":[{"name":"Uprise Health\/Inflexxion, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkat","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"Ephicacy Consulting Group, Iselin, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jody L.","family":"Green","sequence":"additional","affiliation":[{"name":"Uprise Health\/Inflexxion, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"CIT0001","unstructured":"OxyContin (oxycodone hydrochloride) Extended-Release Tablets. Full prescribing information. Purdue Pharma L.P; [accessed 2022 Aug 2]. Available from: http:\/\/app.purduepharma.com\/xmlpublishing\/pi.aspx?id=o"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1300\/J069v23n04_01"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1080\/J354v19n02_04"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2018.304590"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1177\/014556130508400814"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.tripleo.2004.04.006"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1080\/09595239800187001"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1177\/000348940211100212"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.01.039"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-013-0085-x"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113493364"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.235"},{"key":"#cr-split#-CIT0013.1","unstructured":"US Food & Drug Administration. 2020 Joint meeting of the drug safety and risk management advisory committee and the anesthetic and analgesic drug products advisory committee meeting announcement"},{"key":"#cr-split#-CIT0013.2","unstructured":"2020 Sept 10-11 [accessed 2022 Aug 2]. Available from: https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/september-10-11-2020-joint-meeting-drug-safety-and-risk-management-advisory-committee-and-anesthetic"},{"key":"CIT0014","unstructured":"US Food and Drug Administration. Abuse-deterrent opioids \u2013 evaluation and labeling. guidance for industry; 2015 April [accessed 2022 Aug 2]. Available from: https:\/\/www.fda.gov\/media\/84819\/download"},{"key":"CIT0015","unstructured":"US Food and Drug Administration. Abuse-deterrent opioid analgesics; 2021 [accessed 2023 Jan 20]. Available from: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/abuse-deterrent-opioid-analgesics"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2012.08.008"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000001034"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2017.1272397"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3711"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1659"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1037\/0893-164X.15.1.4"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-198507000-00005"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e3181902844"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2017.0415"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4287"},{"key":"CIT0026","unstructured":"US Food & Drug Administration. Joint meeting of the drug safety and risk management advisory committee and the anesthetic and analgesic drug products advisory committee. FDA briefing document. Oxycontin abuse deterrent formulation (ADF); 2020 Sept 10\u201311 [accessed 2022 Aug 2]. Available from: https:\/\/www.fda.gov\/media\/141914\/download"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2023.2178080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T13:31:59Z","timestamp":1681219919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2023.2178080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"alternative-id":["10.1080\/03007995.2023.2178080"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2023.2178080","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"type":"print","value":"0300-7995"},{"type":"electronic","value":"1473-4877"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}